Convergent catalytic asymmetric synthesis of camptothecin analog GI147211C

Tetrahedron

Volumn 53, Issue 32, 1997, Pages 10953-10970

  Fang, Francis G ^a   Bankston, Donald D ^a,b   Huie, Edward M ^a   Johnson, M Ross ^a,c   Kang, Myung Chol ^a,c   LeHoullier, Craig S ^a   Lewis, George C ^a,d   Lovelace, Thomas C ^a   Lowery, Melissa W ^a   McDougald, Darryl L ^a   Meerholz, Clive A ^a   Partridge, John J ^a   Sharp, Matthew J ^a   Xie, Shiping ^a  

^a GLAXOSMITHKLINE   (United States)

^b BAYER AG   (Germany)

^c Trimeris Inc   (United States)

^d AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN DERIVATIVE; DNA TOPOISOMERASE INHIBITOR; LURTOTECAN;

ARTICLE; CATALYSIS; DRUG SYNTHESIS; IN VITRO STUDY; INFRARED SPECTROPHOTOMETRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; REACTION ANALYSIS; STEREOCHEMISTRY;

EID: 0030792219     PISSN: 00404020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0040-4020(97)00357-8     Document Type: Article

References (37)

1. For a review of clinical data relating to the camptothecins see: W. J. Slichenmyer, E. K. Rowinsky, R. C. Donehower, S. H. Kaufmann, J. Nat. Cancer Inst. 1993, 85, 271.
2. Topotecan was approved by the FDA for marketing to treat ovarian cancer on May 29, 1996.
3. Irinotecan was approved by the FDA for marketing to treat colorectal cancer on June 14, 1996.
4. W. D. Kingsbury, J. C. Boehm, D. R. Jakas, K. G. Holden, S. M. Hecht, G. Gallagher, M. J. Caranfa, F. L. McCabe, L. F. Faucette, R. K. Johnson, and R. P. Hertzberg, J. Med. Chem. 1991, 34, 98.
5. S. Sawada, S. Okajima, R. Aiyama, K. Nokata, T. Furuta, T. Yokokura, E. Sugino, K. Yamaguchi, and T. Miyasaka, Chem. Pharm. Bull. 1991, 39, 1446.
6. M.J. Luzzio, J.M. Besterman, D.L. Emerson, M.G. Evans, K. Lackey, P.L. Leitner, G. McIntyre, B. Morton, P.L. Myers, M. Peel, J. M. Sisco, D.D. Sternbach, W.-Q. Tong, A. Truesdale, D.E. Uehling, A. Vuong, and J. Yates, J. Med. Chem. 1995, 38, 395.
7. M. C. Wani, A. W. Nicholas, M. E. Wall, J. Med. Chem. 1987, 30, 2317.
8. (a) D. P. Curran et al, Angew. Chem. Int. Ed. Engl. 1995, 34, 2683.
9. (b) D. P. Curran, H. Liu, H. Josien, and S.-Bo Ko, Tetrahedron, 1996, 52, 11385.
10. a) F. G. Fang, M. W. Lowery, and S. Xie, U.S. Patent 5,491,237 (2/13/96).
11. b) F. G. Fang, S. Xie, and M. W. Lowery, J. Org. Chem. 1994, 59, 6142.
12. For reviews on synthetic efforts in this field see: (a) D. P. Curran, J. Sisko, and P. E. Yeske, Pure Appl. Chem. 1993, 65, 1153.
13. (b) J. C. Cia, C. R. Hutchinson, in The Alkaloids: Chemistry and Pharmacology, A. Brossi, Ed., Academic Press: New York, 1983, vol. 21, p 101.
14. (d) C. R. Hutchinson, Tetrahedron 1981, 37, 1047.
15. (e) A. G. Schultz, Chem. Rev. 1973, 73, 385.
16. For recent synthetic studies towards 1 see: (a) M. Ciufolini and F. Roschangar, Angew. Chem. Int. Ed. Engl. 1996, 35, 1692.
17. (b) J. M. D. Fortunak, J. Kitteringham, A. R. Mastrocola, M. Mellinger, N. J. Sisti, J. L. Wood, and Z.-P. Zhuang, Tetrahedron Lett. 1996, 37, 5683.
18. (c) J. M. D. Fortunak, A. R. Mastrocola, M. Mellinger, N. J. Sisti, J. L. Wood, and Z.-P. Zhang, Tetrahedron Lett. 1996, 37, 5679.
19. (d) S.-s. Jew, K.-d. Ok, H.-j. Kim, M. G. Kim, J. M. Kim, J. M. Hah, Y.-s. Cho, Tetrahedron: Asymmetry 1995, 6, 1245.
20. (e) D. H. Comins, H. Hong, J. K. Saha, and G. Jianhua, J. Org. Chem. 1994, 59, 5120.
21. (f) W. Shen, C. A. Coburn, W. G. Bornman, and S. J. Danishefsky, J. Org. Chem. 1993, 58, 611.
22. D.L. Comins, M.F. Baefsky, and H. Hong, J. Am. Chem. Soc. 1992, 114, 10971.
23. For a recent review see: R. Grigg, V. Sridharan, P. Stevenson, S. Sukirthalingam, and T. Worakun, Tetrahedron 1990, 46, 4003.
24. For a recent review see: H. C. Kolb, M. S. VanNieuwenhze, and K. B. Sharpless, Chem. Rev. 1994, 94, 2483.
25. For some recent results on the intramoleular Heck reaction (cf. 9 to 10) see: D. D. Bankston, F. G. Fang, and S. Xie, J. Org. Chem., manuscript in preparation.
26. I. N. Houpis, A. Molina, A. W. Douglas, L. Xavier, J. Lynch, R. P. Volante, and P. J. Reider, Tetrahedron Lett. 1994, 35, 6811.
27. T. Sugasawa, M. Adachi, K. Sasakura, A. Kitagawa, J. Org. Chem. 1979, 44, 578.
28. cf. J. A. Robl, Synthesis, 1991, 56.
29. For reviews see: (a) O. Mitsunobu, Synthesis 1981, 1.
30. (b) D. L. Hughes, Org. React. 1992, 42, 335.
31. At the time we implemented this solution, no reports on the Mitsunobu reaction of pyridones had appeared in the literature. Subsequently, Comins has published a study on the Mitsonubu reaction of pyridones and the application of this reaction to the synthesis of 1: (a) D. L. Comins and G. Jianhua, Tetrahedron Lett. 1994, 35, 2819.
32. (b) D. L. Comins, H. Hong, and G. Jianhua, Tetrahedron Lett. 1994, 35, 5331. See also reference 15e.
33. For a review see: R. F. Heck, Org. React. 1982, 27, 345.
34. For a nickel-mediated cyclization of a chloroaromatic system see: M. Mori, S. Kudo, and Y. Ban, J. Chem. Soc., Perkin Trans. I 1979, 771.
35. A similar strategy for palladium removal has been developed in the synthesis of the angiotensin II receptor antagonist losartan: R. D. Larsen, A. O. King, C. Y. Chen, E. G. Gorley, B. S. Foster, F. E. Roberts, C. Yang, D. R. Lieberman, R. A. Reamer, D. M. Tschaen, T. R. Verhoeven, P. J. Reider, Y. S. Lo, L. T. Rossano, A. S. Brookes, D. Meloni, J. R. Moore, and J. F. Arnett, J. Org. Chem. 1994, 59, 6391.
36. The biological activity of this compound will be reported elsewhere.
37. N. Menschutkin, Z. Phys. Chem. 1890, 6, 41.